1. Home
  2. ESGR vs CRSP Comparison

ESGR vs CRSP Comparison

Compare ESGR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESGR
  • CRSP
  • Stock Information
  • Founded
  • ESGR 2001
  • CRSP 2013
  • Country
  • ESGR Bermuda
  • CRSP Switzerland
  • Employees
  • ESGR N/A
  • CRSP N/A
  • Industry
  • ESGR Property-Casualty Insurers
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ESGR Finance
  • CRSP Health Care
  • Exchange
  • ESGR Nasdaq
  • CRSP Nasdaq
  • Market Cap
  • ESGR 4.7B
  • CRSP 4.3B
  • IPO Year
  • ESGR N/A
  • CRSP 2016
  • Fundamental
  • Price
  • ESGR $324.10
  • CRSP $44.03
  • Analyst Decision
  • ESGR
  • CRSP Buy
  • Analyst Count
  • ESGR 0
  • CRSP 18
  • Target Price
  • ESGR N/A
  • CRSP $76.60
  • AVG Volume (30 Days)
  • ESGR 83.8K
  • CRSP 1.8M
  • Earning Date
  • ESGR 11-12-2024
  • CRSP 11-05-2024
  • Dividend Yield
  • ESGR N/A
  • CRSP N/A
  • EPS Growth
  • ESGR 51.73
  • CRSP N/A
  • EPS
  • ESGR 66.06
  • CRSP N/A
  • Revenue
  • ESGR $1,067,000,000.00
  • CRSP $202,829,000.00
  • Revenue This Year
  • ESGR N/A
  • CRSP N/A
  • Revenue Next Year
  • ESGR N/A
  • CRSP $758.18
  • P/E Ratio
  • ESGR $4.90
  • CRSP N/A
  • Revenue Growth
  • ESGR 17.90
  • CRSP 19.31
  • 52 Week Low
  • ESGR $262.54
  • CRSP $42.86
  • 52 Week High
  • ESGR $348.48
  • CRSP $91.10
  • Technical
  • Relative Strength Index (RSI)
  • ESGR 44.98
  • CRSP 39.11
  • Support Level
  • ESGR $322.96
  • CRSP $43.40
  • Resistance Level
  • ESGR $327.50
  • CRSP $53.97
  • Average True Range (ATR)
  • ESGR 1.58
  • CRSP 2.37
  • MACD
  • ESGR -0.30
  • CRSP -0.78
  • Stochastic Oscillator
  • ESGR 20.93
  • CRSP 9.53

About ESGR Enstar Group Limited

Enstar Group Ltd is a (re)insurance group that offers capital release solutions through its network of group companies. It seeks to create value by managing (re)insurance companies and portfolios of (re)insurance and other liability businesses in run-off and striving to generate an attractive risk-adjusted return from its investment portfolio. Its operations are through four reportable segments: Run-off, Assumed Life, Investments, and Legacy Underwriting.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: